经导管动脉栓塞化疗联合射频消融术治疗原发性肝细胞肝癌的效果观察

Clinical efficacy of transcatheter arterial chemoembolization combined radio frequency ablation in primary hepatocellular carcinoma

目的探讨选择性经导管动脉栓塞化疗(TACE)联合射频消融术(RFA)治疗原发性肝细胞肝癌的疗效及对患者生存的影响。方法将78例原发性肝细胞肝癌患者按治疗方式不同分为对照组(TACE治疗,n=37)和研究组(TACE联合RFA治疗,n=41)。对比两组患者的临床疗效、并发症发生情况及生存情况。结果研究组患者总有效率及疾病控制率均高于对照组,差异均有统计学意义(P<0.05)。两组患者并发症总发生率比较,差异无统计学意义(P>0.05)。研究组患者1年、2年、3年生存率均高于对照组,差异均有统计学意义(P<0.05)。结论原发性肝细胞肝癌经选择性TACE联合RFA治疗疗效确切,可有限延长患者的生存时间,临床应用前景可观。

Objective To investigate the efficacy of transcatheter arterial chemoembolization(TACE)combined radio frequency ablation(RFA)in the treatment of primary hepatocellular carcinoma and its influence on survival.Method A total of 78 patients with primary hepatocellular carcinoma were divided into the control group(n=37,received TACE)and study group(n=41,received TACE+RFA)according to treatment methods.The clinical efficacy,complications and survival of the two groups were compared.Result The total effective rate and disease control rate of the study were significantly higher than those of the control group(P<0.05);there was no significant difference for the incidence of complications between the two groups(P>0.05);the 1-,2-,and 3-year survival rate of the study group were higher than those of the control group(P<0.05).Conclusion The selective TACE combined RFA treatment for primary hepatocellular carcinoma has a definite curative effect,which can prolong the survival time of patients to a limited extent,and the clinical application prospects are promising.